SEQUENCE LISTING

<110>  ZymoGenetics, Inc.
       Busby, Sharon
       Gross, Jane
       Visich, Jennifer
       Nestorov, Ivan
       Munafo, Alain
       Papasouliotis, Orestis
       Pena Rossi, Claudia
 
<120>  DOSING METHODS FOR TREATING AUTOIMMUNE DISEASES USING A TACI-IG FUSION 
       MOLECULE SUCH AS ATACICEPT

<130>  07-15PC

<150> 60/943,618          
<151> 2007-06-13  

<150>  61/024,031         
<151> 2008-01-28  

<160>  2     

<170>  PatentIn version 3.4

<210>  1
<211>  154
<212>  PRT
<213>  TACI

<400>  1

Met Ser Gly Leu Gly Arg Ser Arg Arg Gly Gly Arg Ser Arg Val Asp 
1               5                   10                  15      
Gln Glu Glu Arg Phe Pro Gln Gly Leu Trp Thr Gly Val Ala Met Arg 
            20                  25                  30          
Ser Cys Pro Glu Glu Gln Tyr Trp Asp Pro Leu Leu Gly Thr Cys Met 
        35                  40                  45              
Ser Cys Lys Thr Ile Cys Asn His Gln Ser Gln Arg Thr Cys Ala Ala 
    50                  55                  60                  
Phe Cys Arg Ser Leu Ser Cys Arg Lys Glu Gln Gly Lys Phe Tyr Asp 
65                  70                  75                  80  
His Leu Leu Arg Asp Cys Ile Ser Cys Ala Ser Ile Cys Gly Gln His 
                85                  90                  95      
Pro Lys Gln Cys Ala Tyr Phe Cys Glu Asn Lys Leu Arg Ser Pro Val 
            100                 105                 110         
Asn Leu Pro Pro Glu Leu Arg Arg Gln Arg Ser Gly Glu Val Glu Asn 
        115                 120                 125             
Asn Ser Asp Asn Ser Gly Arg Tyr Gln Gly Leu Glu His Arg Gly Ser 
    130                 135                 140                 
Glu Ala Ser Pro Ala Leu Pro Gly Leu Lys 
145                 150                 


<210>  2
<211>  348
<212>  PRT
<213>  Human Immunoglobulin-Constant Domain Fc5

<400>  2

Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly 
1               5                   10                  15      
Ala Val Phe Val Ser Leu Ser Gln Glu Ile His Ala Glu Leu Arg Arg 
            20                  25                  30          
Phe Arg Arg Ala Met Arg Ser Cys Pro Glu Glu Gln Tyr Trp Asp Pro 
        35                  40                  45              
Leu Leu Gly Thr Cys Met Ser Cys Lys Thr Ile Cys Asn His Gln Ser 
    50                  55                  60                  
Gln Arg Thr Cys Ala Ala Phe Cys Arg Ser Leu Ser Cys Arg Lys Glu 
65                  70                  75                  80  
Gln Gly Lys Phe Tyr Asp His Leu Leu Arg Asp Cys Ile Ser Cys Ala 
                85                  90                  95      
Ser Ile Cys Gly Gln His Pro Lys Gln Cys Ala Tyr Phe Cys Glu Asn 
            100                 105                 110         
Lys Leu Arg Ser Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro 
        115                 120                 125             
Pro Cys Pro Ala Pro Glu Ala Glu Gly Ala Pro Ser Val Phe Leu Phe 
    130                 135                 140                 
Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val 
145                 150                 155                 160 
Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe 
                165                 170                 175     
Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro 
            180                 185                 190         
Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr 
        195                 200                 205             
Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val 
    210                 215                 220                 
Ser Asn Lys Ala Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala 
225                 230                 235                 240 
Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg 
                245                 250                 255     
Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly 
            260                 265                 270         
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro 
        275                 280                 285             
Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser 
    290                 295                 300                 
Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln 
305                 310                 315                 320 
Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His 
                325                 330                 335     
Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 
            340                 345             

